![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLCO1B1 |
Gene summary for SLCO1B1 |
![]() |
Gene information | Species | Human | Gene symbol | SLCO1B1 | Gene ID | 10599 |
Gene name | solute carrier organic anion transporter family member 1B1 | |
Gene Alias | HBLRR | |
Cytomap | 12p12.1 | |
Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | A0A024RAU7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10599 | SLCO1B1 | NAFLD1 | Human | Liver | NAFLD | 8.08e-07 | 6.13e-01 | -0.04 |
10599 | SLCO1B1 | S41 | Human | Liver | Cirrhotic | 2.80e-06 | 8.19e-01 | -0.0343 |
10599 | SLCO1B1 | S43 | Human | Liver | Cirrhotic | 7.09e-07 | -1.15e-01 | -0.0187 |
10599 | SLCO1B1 | HCC1_Meng | Human | Liver | HCC | 4.97e-92 | 5.28e-02 | 0.0246 |
10599 | SLCO1B1 | HCC2_Meng | Human | Liver | HCC | 4.80e-10 | -3.01e-01 | 0.0107 |
10599 | SLCO1B1 | cirrhotic1 | Human | Liver | Cirrhotic | 6.03e-09 | -2.98e-01 | 0.0202 |
10599 | SLCO1B1 | cirrhotic2 | Human | Liver | Cirrhotic | 4.58e-11 | -2.91e-01 | 0.0201 |
10599 | SLCO1B1 | cirrhotic3 | Human | Liver | Cirrhotic | 1.33e-03 | -3.01e-01 | 0.0215 |
10599 | SLCO1B1 | HCC1 | Human | Liver | HCC | 7.90e-25 | 4.17e+00 | 0.5336 |
10599 | SLCO1B1 | HCC2 | Human | Liver | HCC | 7.26e-28 | 4.84e+00 | 0.5341 |
10599 | SLCO1B1 | Pt13.a | Human | Liver | HCC | 1.71e-02 | -1.25e-01 | 0.021 |
10599 | SLCO1B1 | Pt13.b | Human | Liver | HCC | 7.39e-08 | -1.80e-01 | 0.0251 |
10599 | SLCO1B1 | Pt14.b | Human | Liver | HCC | 3.55e-04 | -1.75e-02 | 0.018 |
10599 | SLCO1B1 | Pt14.d | Human | Liver | HCC | 2.82e-04 | -2.17e-01 | 0.0143 |
10599 | SLCO1B1 | S016 | Human | Liver | HCC | 8.11e-03 | -3.01e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:0015721 | Liver | NAFLD | bile acid and bile salt transport | 10/1882 | 30/18723 | 4.67e-04 | 6.74e-03 | 10 |
GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
GO:001943911 | Liver | Cirrhotic | aromatic compound catabolic process | 202/4634 | 467/18723 | 6.93e-19 | 1.28e-16 | 202 |
GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
GO:0006787 | Liver | Cirrhotic | porphyrin-containing compound catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033015 | Liver | Cirrhotic | tetrapyrrole catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033013 | Liver | Cirrhotic | tetrapyrrole metabolic process | 24/4634 | 59/18723 | 5.06e-03 | 2.62e-02 | 24 |
GO:0042167 | Liver | Cirrhotic | heme catabolic process | 7/4634 | 11/18723 | 7.11e-03 | 3.41e-02 | 7 |
GO:0046149 | Liver | Cirrhotic | pigment catabolic process | 7/4634 | 11/18723 | 7.11e-03 | 3.41e-02 | 7 |
GO:0006778 | Liver | Cirrhotic | porphyrin-containing compound metabolic process | 20/4634 | 49/18723 | 9.60e-03 | 4.35e-02 | 20 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049762 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
hsa0497611 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLCO1B1 | SNV | Missense_Mutation | c.1126N>T | p.Ile376Phe | p.I376F | Q9Y6L6 | protein_coding | tolerated(1) | benign(0) | TCGA-91-6831-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLCO1B1 | SNV | Missense_Mutation | c.1363C>A | p.Pro455Thr | p.P455T | Q9Y6L6 | protein_coding | tolerated(0.3) | benign(0.065) | TCGA-97-7554-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD | |
SLCO1B1 | SNV | Missense_Mutation | c.248N>G | p.Phe83Cys | p.F83C | Q9Y6L6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-18-3417-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
SLCO1B1 | SNV | Missense_Mutation | c.940C>A | p.Gln314Lys | p.Q314K | Q9Y6L6 | protein_coding | tolerated(1) | benign(0.003) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SLCO1B1 | SNV | Missense_Mutation | rs778697943 | c.280C>A | p.Pro94Thr | p.P94T | Q9Y6L6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-21-1082-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | SNV | Missense_Mutation | novel | c.1147N>G | p.Ile383Val | p.I383V | Q9Y6L6 | protein_coding | tolerated(0.07) | benign(0.019) | TCGA-21-1083-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | SNV | Missense_Mutation | c.364A>T | p.Arg122Trp | p.R122W | Q9Y6L6 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-21-5782-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLCO1B1 | SNV | Missense_Mutation | novel | c.311N>A | p.Met104Lys | p.M104K | Q9Y6L6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-21-A5DI-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | SNV | Missense_Mutation | novel | c.1886N>A | p.Ser629Tyr | p.S629Y | Q9Y6L6 | protein_coding | tolerated(1) | benign(0.013) | TCGA-22-5479-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | SD |
SLCO1B1 | SNV | Missense_Mutation | c.1170N>T | p.Met390Ile | p.M390I | Q9Y6L6 | protein_coding | tolerated(1) | benign(0.01) | TCGA-34-5239-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | taxotere | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | Rosuvastatin | ROSUVASTATIN | ||
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | 135650848 | PRAVASTATIN | ||
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | rocuronium | ROCURONIUM | 25279974 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | ticagrelor | TICAGRELOR | 25935875 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | CLOFIBRATE | CLOFIBRATE | 16316932 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | atrasentan | ATRASENTAN | 16513443 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | rifampin | RIFAMPIN | 22562052,21709081,24420746,19374892 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | GEMFIBROZIL | GEMFIBROZIL | 16316932 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | FENOFIBRATE | FENOFIBRATE | 16316932 | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | nateglinide | NATEGLINIDE | 18187595 |
Page: 1 2 3 4 5 6 7 8 |